News

Monday November 21, 2022

Destiny Pharma’s AMR Paper

It is AMR Awareness Week!  The World Health Organisation has declared that Anti-Microbial Resistance (AMR) is one of the top 10 global public health threats facing humanity.  Destiny Pharma is […]

Friday November 18, 2022

Dr Bill Love speaks to Proactive Investors about how Destiny Pharma is addressing the Gl...

AMR is associated with the deaths of five million people worldwide each year.  It has been estimated that, by 2050, the global death toll from AMR will rise to 10 […]

Tuesday November 15, 2022

XF-73 Dermal infection project advances into clinically enabling safety study with US Go...

Destiny Pharma plc (“Destiny Pharma” or “the Company”) XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID Brighton, United Kingdom, […]

Monday November 14, 2022

New report highlights fast growing market for Live Biotherapeutics, Destiny Pharma’...

A new report highlights a fast growing market for Live Biotherapeutics, reaching $2.6bn by 2030.  Destiny Pharma’s NTCD-M3 preventing C. difficile infections is leading play in this sector.  View the […]